Braxia Scientific to Present at H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022
TORONTO, ONTARIO September 9, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Annual Global Investment Conference being held in New York, September 12-14, 2022. CEO Dr. Roger McIntyre will present virtually during the conference providing a update on its recently acquired U.S. based telemedicine business, KetaMD, as well as its progress expanding the clinical research infrastructure required to execute on the Company’s growing pipeline of registered clinical trials alongside third-party sponsors. The on-demand session will be available at 7:00 a.m. ET Monday September 12, 2022. Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright. About Braxia...
Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients
TORONTO, ONTARIO August 29, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the first quarter ended June 30, 2022. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for the disclosure documents of issuers across Canada, at www.SEDAR.com. “We are proud to have launched KetaMD in the U.S. so that we can begin addressing the needs of millions lacking access to innovative treatments for mental health disorders such as depression, anxiety, bipolar disorder and post-traumatic stress disorder (PTSD),” said Dr. Roger McIntyre, CEO, Braxia...
Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with Plans to Expand Across the U.S.
TORONTO, ONTARIO, Aug. 3, 2022 - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FSE: 4960), a leader in the treatment and research of mental health conditions, is pleased to announce it has acquired 100% of the issued and outstanding stock of KetaMD, Inc. ("KetaMD") (the "Transaction"). KetaMD is a U.S. based, privately-held, innovative telemedicine company, with a mission to address mental health challenges via access to technology-facilitated ketamine-based treatments. KetaMD Logo (CNW Group/Braxia Scientific Corp.) KetaMD's end-to-end telemedicine platform, utilizing leading technology, provides access to safe, affordable, and potentially life-changing at-home ketamine treatments for people suffering from depression and related mental health conditions. Treatments are medically supervised, guided virtually by registered nurses with mental health expertise, and backed by the world's leading psychiatrists and researchers in depression. KetaMD's integration of ketamine and telemedicine is guided by best practices...
Braxia Scientific to Present at H.C. Wainwright Global Investment Conference, Miami from May 24-26, 2022
TORONTO, ONTARIO May 19, 2022 - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Investment Conference from May 24 – 26, 2022 in Miami, Florida. Braxia Scientific CEO Dr. Roger McIntyre will present an overview of the Company's business, including its progress on increasing access to novel ketamine and psychedelic treatments for patients with depression and expanding the clinical research infrastructure required to execute on the Company's growing pipeline of registered clinical trials alongside third-party sponsors. Braxia's trials include Canada's first multi-dose psilocybin-assisted therapy trial which commenced in November 2021 and is expected to report preliminary results in the coming weeks. Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright...